Today's report also covers dactylitis in active psoriatic arthritis patients, risankizumab use, and more (1,900 words, 9 minutes, 30 seconds)
Efficacy and safety of deucravacitinib in…
Today's report also covers dactylitis in active psoriatic arthritis patients, risankizumab use, and more (1,900 words, 9 minutes, 30 seconds)